Innovative Minimally Invasive Devices Uromedica offers unique long-term implantable balloon therapies for stress urinary incontinence that are minimally invasive, easily adjustable post-operation, and removable in-office, providing a compelling solution for healthcare providers seeking effective treatments with low patient burden.

Growing Clinical Development The company is actively expanding its product portfolio through clinical trials, including FDA-investigational devices like ACT for female SUI, presenting opportunities to partner with Uromedica in early adoption and future market expansion.

Strong Regulatory Progress Since FDA approval of ProACT in 2015, Uromedica has demonstrated a clear pathway for regulatory clearance, positioning it favorably for sales efforts targeting U.S. clinics and hospitals looking for proven, minimally invasive solutions.

Market Niche Focus Specializing in urinary incontinence devices with a proven track record in over 16,000 patients worldwide, Uromedica targets a specific niche within urology and gynecology markets, ideal for collaborating with distributors serving these specialties.

Potential for Industry Expansion With emerging products and ongoing trials, there are sales opportunities across the broader medical device landscape, especially with hospitals and clinics investing in minimally invasive, adjustable, and removable treatments for pelvic health issues.